Neuroendrocine pancreatic tumours: clinical presentation, biochemical and histopathological findings in 84 patients

Eriksson, Barbro; Arnberg, Henrik; Lindgren, P. G.; Lörelius, Lars‐Erik; Magnusson, Anders; Lundqvist, G.; Skogseid, Britt; Wide, Leif; Wilander, Erik; Öberg, Kjell

doi:10.1111/j.1365-2796.1990.tb00202.x

Cited by 111 publications

(64 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Five-year OS for patients with metastatic NETs has been reported ranging from 26 to 73% in previous large series, showing a rather variable survival that needs to be further stratified (Eriksson et al, 1990;Madeira et al, 1998;Hochwald et al, 2002;Modlin et al, 2003).…”

Section: Discussionmentioning

confidence: 94%

The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract

et al. 2007

View full text Add to dashboard Cite

The World Health Organisation (WHO) classification (2000) is widely used to classify neuroendocrine carcinomas (NECs), yet its prognostic value needs to be confirmed. In this study, patients with metastatic NECs (n ¼ 119) were classified according to WHO guidelines into well differentiated and poorly differentiated (WDNECs and PDNECs). Histological differentiation based on WHO criteria had the highest impact on overall survival (OS) (PDNECs : WDNECs hazard ratio (HR) ¼ 4.02, P ¼ 0.02); however, PDNECs represented only a small percentage of patients (8%). In a WDNEC-restricted analysis, abnormal liver function tests (LFTs) and elevated urinary 5-hydroxyindoleacetic acid (u5HIAA) were independent prognostic factors for survival (HR ¼ 2.65, P ¼ 0.006 and HR ¼ 2.51, P ¼ 0.003, respectively) and were used to create a WDNEC-specific prognostic model (low risk ¼ both normal, intermediate risk ¼ one of them abnormal, high risk ¼ both abnormal). Low-risk WDNECs had the most favourable prognosis (median OS, mOS 8.1 years), which was significantly better compared to both intermediate-risk and high-risk WDNECs (mOS 3.2 and 1.4 years, with P ¼ 0.01 and Po0.001, respectively). High-risk WDNECs displayed the shortest OS (1.3 years), which was similar to that of PDNECs (P ¼ 0.572). This analysis supports the prognostic value of WHO classification for metastatic NECs arising from the gastroenteropancreatic tract; however, risk stratification using readily available u5HIAA and LFTs may be necessary for the heterogeneous group of WDNECs.

show abstract

Section: Discussionmentioning

confidence: 94%

The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract

et al. 2007

View full text Add to dashboard Cite

show abstract

“…In one study, plasma CgA was elevated in 94% of endocrine pancreatic tumours, and pancreatic polypeptide in 74% (Eriksson et al 1990). Elevated CgA levels were even more frequent (99%) in malignant carcinoid and gastroenteropancreatic tumours (99%) (Stridsberg et al 1995), with the highest levels seen in metastatic carcinoid (particularly midgut).…”

Section: General Markers For Neuroendocrine Tumoursmentioning

confidence: 99%

Neuroendocrine tumours.

Barakat¹,

Meeran²,

Bloom³

2004

Endocr Relat Cancer

209

111

View full text Add to dashboard Cite

Neuroendocrine tumours are a heterogeneous group including, for example, carcinoid, gastroenteropancreatic neuroendocrine tumours, pituitary tumours, medullary carcinoma of the thyroid and phaeochromocytomas. They have attracted much attention in recent years, both because they are relatively easy to palliate and because they have indicated the chronic effect of the particular hormone elevated. As neuroendocrine phenotypes became better understood, the definition of neuroendocrine cells changed and is now accepted as referring to cells with neurotransmitter, neuromodulator or neuropeptide hormone production, dense-core secretory granules, and the absence of axons and synapses. Neuroendocrine markers, particularly chromogranin A, are invaluable diagnostically. Study of several neuroendocrine tumours has revealed a genetic etiology, and techniques such as genetic screening have allowed risk stratification and prevention of morbidity in patients carrying the particular mutation. Pharmacological therapy for these often slow-growing tumours, e.g. with somatostatin analogues, has dramatically improved symptom control, and radiolabelled somatostatin analogues offer targeted therapy for metastatic or inoperable disease. In this review, the diagnosis and management of patients with carcinoid, gut neuroendocrine tumours, multiple endocrine neoplasia types 1 and 2, and isolated phaeochromocytoma are evaluated.

show abstract

“…Though some neuroendocrine gastrointestinal tumours can be treated successfully with surgery, neuroendocrine gastroenteropancreatic tumours usually present in a late stage when the disease has already metastasised (17,18). In these cases, the basis for therapy is then not to cure, but to ameliorate clinical symptoms, reduce tumour growth and maintain and improve quality of life.…”

Section: Discussionmentioning

confidence: 99%

Effective treatment of bone metastases from a neuroendocrine tumour of the pancreas with high activities of Indium-111-pentetreotide

et al. 2003

View full text Add to dashboard Cite

Objective: To evaluate therapy with high doses of 111 Indium pentetreotide in a patient with bone metastases from a carcinoid of the pancreas. Case report: A 55-year-old male presented in November 1990 with stomach ache with dorsal irradiation. Ultrasonography and computed tomography (CT-) scans of the abdomen revealed a tumour of the tail of the pancreas and liver metastases. Histological examination revealed a neuroendocrine tumour. Surgery and polychemotherapy were initiated and after seven cycles a tumour regression of 30% was achieved. During follow-up multiple metastases were seen upon bone scintigraphy for which treatment with high doses Indium-111-octreotide was initiated. Materials and methods: The patient underwent eight cycles, with one cycle every 5 weeks. Each treatment consisted of an i.v. injection of 6 GBq Indium-111-pentetreotide. Comparing the results of the first and the last post-treatment scintigraphy, a regression of the number and intensity of uptake in the lesions was found. Bone scintigraphy showed a regression of the skeletal lesions as well, while X-ray, CT-scan and chromogranin-A levels showed stable disease. Conclusion: Results from the treatment of our patient indicate that the use of high dose radiolabelled somatostatin analogues could be of significant use, even in the case of bone metastases. To our knowledge, this is the first report describing therapeutic effects on bone metastases from a neuroendocrine tumour.

show abstract

Neuroendrocine pancreatic tumours: clinical presentation, biochemical and histopathological findings in 84 patients

Cited by 111 publications

References 36 publications

The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract

The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract

Neuroendocrine tumours.

Effective treatment of bone metastases from a neuroendocrine tumour of the pancreas with high activities of Indium-111-pentetreotide

Contact Info

Product

Resources

About